MASS DEVICE Feature Article on Aqua Medical’s First T2D IDE Trial Patient
Aqua Medical says it has successfully treated the first type 2 diabetes patient with its proximal intestinal mucosal ablation (PIMA) procedure in an FDA investigational device exemption (IDE) trial. The clinical-stage medtech developer uses radiofrequency vapor ablation (RFVA) through a standard endoscope without fluoroscopy for the minimally-invasive, outpatient PIMA procedure in the duodenum. The FDA […]